SIRT3 and hepatocellular carcinoma: Therapeutic advances targeting sirtuins are currently being explored as studies suggest modulating SIRT3 abundance via Cyclin-dependent kinase (CDK) 4/6 inhibition may enhance HCC therapy when combined with sorafenib [193].